Therapy-related dose delays in patients receiving bortezomib and PegLD
Bortezomib dose level, mg/m2 . | Patients with at least 1 delay, n, (%) . | Cycles with at least 1 delay,*n, (%) . | Reasons for dose delays that were at least possibly attributable to therapy with bortezomib/PegLD (n) . |
|---|---|---|---|
| 0.90 | 3/6 (50) | 7/34 (21) | Febrile neutropenia (2), Varicella zoster (1), neutropenia (1), neutropenia and fatigue (1), hypotension (1), atrial fibrillation (1) |
| 1.05 | 3/4 (75) | 5/27 (19) | Febrile neutropenia (1), thrombocytopenia (1), neutropenia and thrombocytopenia (1), PPE/HFS (1), fatigue and neuropathy (1) |
| 1.20 | 1/4 (25) | 2/21 (10) | Mucositis and rash (1), fatigue (1) |
| 1.30 | 2/5 (40) | 4/20 (25) | Fatigue (2), thrombocytopenia (1), neutropenia (1), fatigue and anorexia (1) |
| 1.40 | 5/6 (83) | 14/32 (44) | Thrombocytopenia (13), thrombocytopenia and neutropenia (1), and neutropenia (1) |
| 1.50 | 5/6 (83) | 11/34 (32) | Neutropenia (3), leg weakness (2), diarrhea (2), diarrhea with fatigue (1), diarrhea with worsening neuropathy (1), PPE/HFS (1), myalgias (1) |
Bortezomib dose level, mg/m2 . | Patients with at least 1 delay, n, (%) . | Cycles with at least 1 delay,*n, (%) . | Reasons for dose delays that were at least possibly attributable to therapy with bortezomib/PegLD (n) . |
|---|---|---|---|
| 0.90 | 3/6 (50) | 7/34 (21) | Febrile neutropenia (2), Varicella zoster (1), neutropenia (1), neutropenia and fatigue (1), hypotension (1), atrial fibrillation (1) |
| 1.05 | 3/4 (75) | 5/27 (19) | Febrile neutropenia (1), thrombocytopenia (1), neutropenia and thrombocytopenia (1), PPE/HFS (1), fatigue and neuropathy (1) |
| 1.20 | 1/4 (25) | 2/21 (10) | Mucositis and rash (1), fatigue (1) |
| 1.30 | 2/5 (40) | 4/20 (25) | Fatigue (2), thrombocytopenia (1), neutropenia (1), fatigue and anorexia (1) |
| 1.40 | 5/6 (83) | 14/32 (44) | Thrombocytopenia (13), thrombocytopenia and neutropenia (1), and neutropenia (1) |
| 1.50 | 5/6 (83) | 11/34 (32) | Neutropenia (3), leg weakness (2), diarrhea (2), diarrhea with fatigue (1), diarrhea with worsening neuropathy (1), PPE/HFS (1), myalgias (1) |
The data shown include only the first cohort of patients accrued to allow determination of the MTD and DLTs and do not include delays in the 11 patients added at 1.30 mg/m2 for further experience. Dose delays occurring in any cycle are shown.
The fraction shown is the number of unique cycles delayed/total number of cycles given to all patients at this dose level.